NCT04722575View on ClinicalTrials.gov

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

December 15, 2023

Study Completion Date

June 30, 2027

Conditions
Melanoma
Interventions
DRUG

Cobimetinib 20 MG Oral Tablet

Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.

DRUG

Vemurafenib 240 Mg Oral Capsule

960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.

DRUG

Atezolizumab 1200 MG in 20 ML Injection

840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks

Trial Locations (6)

16132

IRCCS San Martino - IST, Genova

20133

Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori, Milan

35128

Istituto Oncologico Veneto, Padua

47014

IRCCS - Istituto Scientifico Romagnolo per la Cura e lo Studio dei Tumori (I.R.S.T) S.r.l., Meldola

50012

Ospedale S.M. Annunziata - Azienda USL Toscana Centro, Bagno a Ripoli

80131

"Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale", Naples

Sponsors
All Listed Sponsors
collaborator

Clinical Research Technology S.r.l.

INDUSTRY

lead

Fondazione Melanoma Onlus

OTHER

NCT04722575 - Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma | Biotech Hunter | Biotech Hunter